NextCell Pharma AB (NXTCL.ST)

SEK 2.42

(-13.57%)

Total Liabilities Summary of NextCell Pharma AB

  • NextCell Pharma AB's latest annual total liabilities in 2024 was 13.68 Million SEK , up 4.49% from previous year.
  • NextCell Pharma AB's latest quarterly total liabilities in 2024 Q3 was 14.1 Million SEK , down -4.06% from previous quarter.
  • NextCell Pharma AB reported annual total liabilities of 13.1 Million SEK in 2023, up 43.7% from previous year.
  • NextCell Pharma AB reported annual total liabilities of 9.11 Million SEK in 2022, up 64.75% from previous year.
  • NextCell Pharma AB reported quarterly total liabilities of 14.1 Million SEK for 2024 Q3, down -4.06% from previous quarter.
  • NextCell Pharma AB reported quarterly total liabilities of 14.7 Million SEK for 2024 Q2, down -3.81% from previous quarter.

Annual Total Liabilities Chart of NextCell Pharma AB (2024 - 2015)

Historical Annual Total Liabilities of NextCell Pharma AB (2024 - 2015)

Year Total Liabilities Total Liabilities Growth
2024 13.68 Million SEK 4.49%
2023 13.1 Million SEK 43.7%
2022 9.11 Million SEK 64.75%
2021 5.53 Million SEK 55.62%
2020 3.55 Million SEK -5.37%
2019 3.75 Million SEK 8.31%
2018 3.46 Million SEK 35.85%
2017 2.55 Million SEK -5.47%
2016 2.7 Million SEK 4.4%
2015 2.58 Million SEK 0.0%

Peer Total Liabilities Comparison of NextCell Pharma AB

Name Total Liabilities Total Liabilities Difference
Alligator Bioscience AB (publ) 106.59 Million SEK 87.158%
Ziccum AB (publ) 6.38 Million SEK -114.293%
Modus Therapeutics Holding AB (publ) 2.35 Million SEK -480.291%
BioArctic AB (publ) 139.5 Million SEK 90.187%
Sprint Bioscience AB (publ) 34.6 Million SEK 60.44%
Mendus AB (publ) 51.22 Million SEK 73.277%
Genovis AB (publ.) 98.04 Million SEK 86.038%
Intervacc AB (publ) 21.68 Million SEK 36.859%
QuiaPEG Pharmaceuticals Holding AB (publ) 26.7 Million SEK 48.745%
Active Biotech AB (publ) 13.4 Million SEK -2.157%
Magle Chemoswed Holding AB (publ) 123.97 Million SEK 88.959%
Bio-Works Technologies AB (publ) 16.11 Million SEK 15.064%
Aptahem AB (publ) 8.99 Million SEK -52.137%
Vicore Pharma Holding AB (publ) 40.85 Million SEK 66.497%
Kancera AB (publ) 17.97 Million SEK 23.857%
Infant Bacterial Therapeutics AB (publ) 46.18 Million SEK 70.357%
Fluicell AB (publ) 8.91 Million SEK -53.551%
Saniona AB (publ) 86.08 Million SEK 84.098%
Lipigon Pharmaceuticals AB (publ) 5.15 Million SEK -165.395%
Biovica International AB (publ) 34.76 Million SEK 60.626%
Spago Nanomedical AB (publ) 11.66 Million SEK -17.321%
AcouSort AB (publ) 10.37 Million SEK -31.905%
Xintela AB (publ) 14.01 Million SEK 2.326%
Abliva AB (publ) 16.78 Million SEK 18.425%
Egetis Therapeutics AB (publ) 214.6 Million SEK 93.621%
Karolinska Development AB (publ) 11.56 Million SEK -18.325%
OncoZenge AB (publ) 1.69 Million SEK -705.712%
Amniotics AB (publ) 10.54 Million SEK -29.791%
2cureX AB (publ) 2.93 Million SEK -366.407%
CombiGene AB (publ) 4.15 Million SEK -229.381%
Asarina Pharma AB (publ) 4.42 Million SEK -209.287%
Calliditas Therapeutics AB (publ) 1.56 Billion SEK 99.126%
Camurus AB (publ) 414.81 Million SEK 96.7%
Corline Biomedical AB 6.78 Million SEK -101.636%
IRLAB Therapeutics AB (publ) 61.35 Million SEK 77.689%
Isofol Medical AB (publ) 19.16 Million SEK 28.569%
I-Tech AB 16.2 Million SEK 15.526%
Hansa Biopharma AB (publ) 1.18 Billion SEK 98.846%
Cyxone AB (publ) 4.69 Million SEK -191.629%
ExpreS2ion Biotech Holding AB (publ) 13.32 Million SEK -2.709%
Biosergen AB 5.08 Million SEK -169.205%
Cantargia AB (publ) 54.97 Million SEK 75.097%
Xspray Pharma AB (publ) 71.85 Million SEK 80.948%
Elicera Therapeutics AB (publ) 13.77 Million SEK 0.599%
Nanologica AB (publ) 79.32 Million SEK 82.744%
SynAct Pharma AB 51.83 Million SEK 73.591%
Annexin Pharmaceuticals AB (publ) 7.94 Million SEK -72.211%
Stayble Therapeutics AB (publ) 5.19 Million SEK -163.507%
LIDDS AB (publ) 3.75 Million SEK -264.458%
Lipum AB (publ) 7.53 Million SEK -81.601%
BioInvent International AB (publ) 90.45 Million SEK 84.866%
Alzinova AB (publ) 9.33 Million SEK -46.705%
Oncopeptides AB (publ) 181.59 Million SEK 92.462%
Pila Pharma AB (publ) 1.79 Million SEK -663.047%
Guard Therapeutics International AB (publ) 18.49 Million SEK 25.981%
Scandinavian ChemoTech AB (publ) 3.83 Million SEK -256.672%
Simris Alg AB (publ) 148.93 Million SEK 90.809%
Diamyd Medical AB (publ) 71.11 Million SEK 80.752%
Xbrane Biopharma AB (publ) 482.17 Million SEK 97.161%
Ascelia Pharma AB (publ) 12.74 Million SEK -7.416%
Diagonal Bio AB (publ) 7.26 Million SEK -88.554%